It's turning out to be a good week for Isis Pharmaceuticals (ISIS +0.3%): the company forges a...

|By:, SA News Editor

It's turning out to be a good week for Isis Pharmaceuticals (ISIS +0.3%): the company forges a partnership with AstraZeneca (AZN +0.7%) to use Isis' antisense technology to develop therapies against five cancer targets. AstraZeneca will make $31M in upfront and near-term payments, as well as further milestone, license fee and royalty payments. Yesterday, Isis said it is expanding its partnership with Biogen. (PR)